Research Overview: Seroflo Rotacap
Seroflo Rotacap 100 mcg is a combination respiratory medication manufactured by Cipla containing salmeterol xinafoate (25 mcg) and fluticasone propionate (100 mcg) in dry powder inhalation capsules. This dual-action formulation represents a long-acting beta-2 agonist (LABA) paired with an inhaled corticosteroid (ICS) for comprehensive respiratory research applications. Researchers at Stroid UK Shop investigate this combination therapy model to examine synergistic mechanisms between bronchodilation and anti-inflammatory pathways in pulmonary tissue studies.
Research Applications
Laboratory investigations examine how the salmeterol component provides sustained beta-2 receptor agonism for up to 12 hours in respiratory models, while fluticasone propionate delivers potent anti-inflammatory effects through glucocorticoid receptor modulation. Researchers studying other drugs evaluate this combination’s effectiveness in chronic obstructive pulmonary disease (COPD) and asthma research models. The dry powder delivery system allows precise dosing studies and bioavailability assessments in controlled laboratory environments. Scientists also investigate drug deposition patterns and pharmacokinetic interactions between the two active components in various respiratory research protocols.
Technical Specifications
| Manufacturer | Cipla Limited |
|---|---|
| Active Components | Salmeterol xinafoate 25 mcg + Fluticasone propionate 100 mcg |
| Formulation | Dry powder inhalation capsules |
| Dosage Form | Rotacap (hard gelatin capsules for inhaler use) |
| Storage Conditions | Store below 25°C, protect from moisture |
| Shelf Life | Verify with supplier documentation |
Researchers examining SARMs and peptides often include respiratory function assessments in their comprehensive safety evaluation protocols.
Compliance Statement
Seroflo Rotacap 100 mcg is supplied strictly for in-vitro research purposes only. This product is not intended for human consumption, clinical trials, or therapeutic applications. All research must comply with appropriate laboratory safety protocols and regulatory guidelines for pharmaceutical research compounds. Proper disposal procedures must be followed according to local environmental regulations.



